Back to top
more

Athenex, Inc. (ATNX)

(Delayed Data from NSDQ)

$10.12 USD

10.12
252,235

+0.19 (1.91%)

Updated May 3, 2019 04:00 PM ET

After-Market: $10.09 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -7.05% and 40.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Swedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 12.50% and 16.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -76.92% and 6.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 11.22% and 11.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3

by Zacks Equity Research

Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.

Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

by Zacks Equity Research

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

by Zacks Equity Research

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

    Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

    by Zacks Equity Research

    Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

    Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

    by Zacks Equity Research

    The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

      Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC

      by Zacks Equity Research

      The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.

        Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug

        by Zacks Equity Research

        The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.